Fisher syndrome as an immune-related adverse event after using pembrolizumab but not nivolumab
- 28.02.2021
- Letter to the Editor
Erschienen in:
- Verfasst von
- Kiyotaka Nakamagoe
- Takeshi Yamada
- Sho Okune
- Toshikazu Moriwaki
- Akira Tamaoka
- Erschienen in
- Acta Neurologica Belgica | Ausgabe 5/2021
Auszug
Antibodies against the programmed cell death 1 (PD-1) receptor, such as pembrolizumab and nivolumab, are associated with immune-related adverse events (irAEs). These drugs are known to cause various autoimmune diseases via abnormal immune responses. Pembrolizumab has been reported to cause immune-mediated neuropathies such as Fisher syndrome (FS) [1, 2], which is regarded as a subtype of Guillain–Barré syndrome (GBS). FS includes a trilogy of disorders: ataxia of the extremities/body trunk, decreased tendon reflexes, and ocular movement dysfunction. However, there are only a few previous reports of FS developing due to checkpoint immunotherapy including pembrolizumab and nivolumab [1, 2]. Here, we report the first case in which a patient experienced an irAE such as FS with pembrolizumab, but not after using a different antibody against PD-1 receptor, nivolumab. …
Anzeige
- Titel
- Fisher syndrome as an immune-related adverse event after using pembrolizumab but not nivolumab
- Verfasst von
-
Kiyotaka Nakamagoe
Takeshi Yamada
Sho Okune
Toshikazu Moriwaki
Akira Tamaoka
- Publikationsdatum
- 28.02.2021
- Verlag
- Springer International Publishing
- Erschienen in
-
Acta Neurologica Belgica / Ausgabe 5/2021
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993 - DOI
- https://doi.org/10.1007/s13760-021-01623-3
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
